Two Biotech CEOs Indicted on Securities Fraud Charges


This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit

Former chief executive of CytoDyn and the CEO of a company that managed its clinical trials allegedly made fraudulent claims about experimental drug

Two biotechnology industry executives were indicted on criminal charges that they defrauded investors when making claims about an experimental drug, federal prosecutors said Tuesday.

A federal grand jury in Maryland handed up the indictments for Nader Pourhassan, the former chief executive of CytoDyn Inc., and Kazem Kazempour, whose company managed CytoDyn‘s clinical drug trials, the Justice Department said.


Please enter your comment!
Please enter your name here